Skip to main content

Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer

World Journal of Surgery volume 42, pages 114–122 (2018)Cite this article

Abstract

Background

To determine whether 18F-fluoro-2-deoxyglucose (18F-FDG)-PET/CT is useful for predicting the BRAF V600E mutation status of a primary papillary thyroid carcinoma (PTC).

Methods

A retrospective analysis was performed in 108 patients who underwent 18F-FDG positron emission tomography–computed tomography (PET/CT) for staging before thyroidectomy and BRAF analysis in biopsy-confirmed PTC. The maximum standardized uptake value (SUVmax) of the primary tumor was calculated according to FDG accumulation. Univariate and multivariate analyses were performed to assess the association between the SUVmax and clinicopathological variables.

Results

The BRAF V600E mutation was detected in 71 of 108 (65.7%) patients. In all subjects, the tumor size and BRAF V600E mutation were independently related to the SUVmax according to multivariate analyses (P = 0.002 and 0.007, respectively). The SUVmax was significantly higher in tumors with the BRAF V600E mutation than in tumors with wild-type BRAF (10.24 ± 11.89 versus 4.02 ± 3.86; P = 0.007). In the tumor size >1 cm subgroup, the BRAF V600E mutation was the only factor significantly associated with the SUVmax (P = 0.016). A SUVmax cutoff level of 4.9 was determined to be significant for predicting the BRAF V600E mutation status (sensitivity 77.4%, specificity 100.0%, area under the curve 0.929; P < 0.0001) according to ROC curve analysis.

Conclusions

The BRAF V600E mutation is independently associated with high 18F-FDG uptake in PTC, especially in those with a tumor size >1 cm.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Lee JW, Lee SM, Lee DH et al (2013) Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med 54:1230–1236

    CAS  Article  PubMed  Google Scholar 

  2. Rosenbaum-Krumme SJ, Gorges R, Bockisch A et al (2012) (1)(8)F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging 39:1373–1380

    Article  PubMed  Google Scholar 

  3. Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-d-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505

    CAS  Article  PubMed  Google Scholar 

  4. Wang W, Larson SM, Fazzari M et al (2000) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107–1113

    CAS  PubMed  Google Scholar 

  5. Bertagna F, Treglia G, Piccardo A et al (2012) Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J Clin Endocrinol Metab 97:3866–3875

    CAS  Article  PubMed  Google Scholar 

  6. Koh J, Choi JR, Han KH et al (2013) Proper indication of BRAF V600E mutation testing in fine-needle aspirates of thyroid nodules. PLoS ONE 8:e64505

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Yoon M, Jung SJ, Kim TH et al (2016) Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocr Res 41:64–69

    CAS  Article  PubMed  Google Scholar 

  8. Yoon S, An YS, Lee SJ et al (2015) Relation between F-18 FDG uptake of PET/CT and BRAFV600E mutation in papillary thyroid cancer. Med 94(48):e2063

    CAS  Article  Google Scholar 

  9. Choi EK, Kim SH, Hyun OJ et al (2015) Preoperative 18F-FDG PET/CT as an indicator of clinicopathologic features and BRAFV600E mutation in patients with papillary thyroid cancer. J Nucl Med 56:1665

    Google Scholar 

  10. Yeo M-K, Liang ZL, Oh T et al (2011) Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol 75:555–560

    Article  Google Scholar 

  11. Vaccarella S, Franceschi S, Bray F et al (2016) Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 375:614–617

    Article  PubMed  Google Scholar 

  12. So Y, Chung HW, Kim SK et al (2015) Preoperative FDG PET/CT in papillary thyroid carcinoma for prediction of recurrence. J Nucl Med 56:1643

    Google Scholar 

  13. Sturgeon C, Angelos P (2006) Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. Oncology (Williston Park) 20:397–404; discussion 404:407–398

  14. Renaud F, Gnemmi V, Devos P et al (2014) MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Thyroid 24:1375–1384

    CAS  Article  PubMed  Google Scholar 

  15. Lee X, Gao M, Ji Y et al (2009) Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 16:240–245

    Article  PubMed  Google Scholar 

  16. Xing MZ (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742–762

    CAS  Article  PubMed  Google Scholar 

  17. Lee DY, Hwang SM, An JH et al (2016) Predicting extrathyroidal extension in patients with papillary thyroid microcarcinoma according to a BRAF mutation. Clin Exp Otorhinolaryngol 10:174

    Article  PubMed  PubMed Central  Google Scholar 

  18. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13:184–199

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Tufano RP, Teixeira GV, Bishop J et al (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Med (Baltimore) 91:274–286

    CAS  Article  Google Scholar 

  20. Viola D, Valerio L, Molinaro E et al (2016) Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer 23:R185–R205

    CAS  Article  PubMed  Google Scholar 

  21. Lee WS, Palmer BJA, Garcia A et al (2014) BRAF mutation in papillary thyroid cancer: a cost-utility analysis of preoperative testing. Surgery 156:1569–1578

    Article  PubMed  Google Scholar 

  22. Lee SH, Han S, Lee HS et al (2016) Association between 18F-FDG avidity and the BRAF mutation in papillary thyroid carcinoma. Nucl Med Mol Imaging 50:38–45

    CAS  Article  PubMed  Google Scholar 

  23. Salvatori M, Biondi B, Rufini V (2015) Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur J Endocrinol 173:R115–130

    CAS  PubMed  Google Scholar 

  24. Seo JW, Hwang SH, Cho A et al (2016) Prognostic impact of ultrasonography features and 18F-fluorodeoxyglucose uptake in patients with papillary thyroid microcarcinoma. Clin Exp Otorhinolaryngol 9:62–69

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21:297–308

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. Virk RK, Van Dyke AL, Finkelstein A et al (2013) BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol 26:62–70

    CAS  Article  PubMed  Google Scholar 

  27. Zheng X, Wei S, Han Y et al (2013) Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol 20:2266–2273

    Article  PubMed  Google Scholar 

  28. Walczyk A, Kowalska A, Kowalik A et al (2014) The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf) 80:899–904

    CAS  Article  Google Scholar 

  29. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932–945

    Article  PubMed  Google Scholar 

  30. Choi SJ, Kim TY, Lee JC et al (2008) Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol 1:41–45

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kang KW, Kim S-K, Kang H-S et al (2003) Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100–4104

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by research fund of Chungnam National University, National Research Foundation of Korea (NRF) Grants funded by the Korean government (MEST) (Grant Numbers: 2016R1D1A1B04932112, 2016R1A2A2A05005220, 2015R1D1A1A01057717).

Author information

Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Research Institute for Medical Science, College of Medicine, Chungnam National University, 640 Daesa-Dong, Chung-Gu, Daejeon, 301-721, Republic of Korea

    Jae Won Chang, Ki Wan Park, Jae Hyung Heo, Seung-Nam Jung & Bon Seok Koo

  2. Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

    Lihua Liu

  3. Department of Nuclear Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

    Sung Min Kim

  4. Clinical Trial Center, Chungnam National University Hospital, Daejeon, Republic of Korea

    In Sun Kwon

Authors
  1. Jae Won Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ki Wan Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae Hyung Heo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seung-Nam Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lihua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sung Min Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. In Sun Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bon Seok Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bon Seok Koo.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chang, J.W., Park, K.W., Heo, J.H. et al. Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer. World J Surg 42, 114–122 (2018). https://doi.org/10.1007/s00268-017-4136-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-017-4136-y